


324

9. An intermediate compound of general formula (1-5) according to claim 7,



whereby R¹, R⁶, R⁷, R⁸ and m have the meaning according to claim 1.

10. Use of a compound of formula 1-6 for the manufacture of a compound of formula (I) according to claim 1.

11. Use of a compound of general formula (I) according to any of claims 1 to 6 for the treatment or prophylaxis of diseases.

12. Use of a compound of general formula (I) according to claim 11, whereby the diseases are hyperproliferative diseases and/or disorders responsive to induction of apoptosis.

13. Use of a compound of general formula (I) according to claim 12, whereby the hyperproliferative diseases and/or disorders responsive to induction of apoptosis are haematological tumours, solid tumours and/or metastases thereof.

14. Use of a compound of formula (I) according to claim 13, whereby the tumors are cervical -, breast -, non-small cell lung -, prostate -, colon - or melanoma tumors and/or metastases thereof.


15. A pharmaceutical composition comprising at least one compound of general formula (I) according to any of claims 1 to 6, together with at least one pharmaceutically acceptable auxiliary.

325

16. A composition according to claim 15 for the treatment of haematological tumours, solid tumours and/or metastases thereof.

17. A combination comprising one or more first active ingredients selected from a
5 compound of general formula (I) according to any of claims 1 to 6, and one or
more second active ingredients selected from chemotherapeutic anti-cancer
agents and target-specific anti-cancer agents.

9. An intermediate compound of general formula (1-5) according to claim 7,



whereby R^1 , R^6 , R^7 , R^8 and m have the meaning according to claim 1.

10. Use of a compound of formula 1-6 for the manufacture of a compound of formula (I) according to claim 1.

11. A compound of general formula (I) according to any of claims 1 to 6 for use in the treatment or prophylaxis of diseases.

12. The compound of general formula (I) according to claim 11, whereby the diseases are hyperproliferative diseases and/or disorders responsive to induction of apoptosis.

13. The compound of general formula (I) according to claim 12, whereby the hyperproliferative diseases and/or disorders responsive to induction of apoptosis are haematological tumours, solid tumours and/or metastases thereof.

14. The compound of general formula (I) according to claim 13, whereby the tumors are cervical -, breast -, non-small cell lung -, prostate -, colon - or melanoma tumors and/or metastases thereof.

15. A pharmaceutical composition comprising at least one compound of general formula (I) according to any of claims 1 to 6, together with at least one pharmaceutically acceptable auxiliary.

16. A composition according to claim 15 for use in the treatment of haematological tumours, solid tumours and/or metastases thereof.

17. A combination comprising one or more first active ingredients selected from a compound of general formula (I) according to any of claims 1 to 6, and one or more second active ingredients selected from chemotherapeutic anti-cancer agents and target-specific anti-cancer agents.

18. Use of a compound of general formula (I) according to any of claims 1 to 6 in the manufacture of a medicament for the treatment or prophylaxis of diseases.

19. The use according to claim 18, whereby the diseases are hyperproliferative diseases and/or disorders responsive to induction of apoptosis.

20. The use according to claim 19, whereby the hyperproliferative diseases and/or disorders responsive to induction of apoptosis are haematological tumours, solid tumours and/or metastases thereof.

21. The use according to claim 20, whereby the tumors are cervical -, breast -, non-small cell lung -, prostate -, colon - or melanoma tumors and/or metastases thereof.

22. Use of a composition according to claim 15 in the manufacture of a medicament for the treatment of haematological tumours, solid tumours and/or metastases thereof.